D. Atieh

发表

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.

D. Lake, C. Hudis, L. Norton, 2009 .

Targeted Therapy For Breast Cancer

L. Vahdat, D. Atieh, 2008 .

A phase II trial of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in patients with metastatic breast cancer.

L. Vahdat, M. Modiano, L. Brafman, 2004, Journal of Clinical Oncology.